Biogen exercises option with Ionis for spinal muscular atrophy
Biogen paid Ionis a US $ 60 million one-time upfront payment
Biogen paid Ionis a US $ 60 million one-time upfront payment
The report underscores significant advancements in healthcare delivery, showcasing how GenAI facilitates improved diagnostic accuracy, operational efficiency and patient engagement
US FDA approval based on NEURO-TTRansform Phase III results
This development is a strategic part of the company's commitment to bolstering its position in the advanced pharmaceutical intermediates segment
The sBLA is supported by a usability study which confirmed that individuals over 18 years of age could self-administer
The launch of Elores in Ecuador is expected to open the doors for the entry of the novel antibiotic adjuvant entity in other important Latin American countries
The introduction of 'Definisse Core Filler' is a testament to the company's premium scientific-based innovation
‘Sanjeevani’ aims to raise awareness and encourage conversations around the silent cancer epidemic
The partnership acknowledges the increasing mental health challenges faced by students in today's society
Subscribe To Our Newsletter & Stay Updated